E uiga i le kanesa / togafitiga / faʻafomaʻi-faʻafitauli / testicular-kanesa
Togafitiga Faʻafomaʻi e togafitia ai le kanesa faʻapitoa
Faʻataʻitaʻiga 1-4 o le 4
Nivolumab ma Ipilimumab i le togafitia o tagata mamaʻi ma le papala o le tino
Lenei vaega II suʻesuʻega suʻesuʻega nivolumab ma ipilimumab i le togafitia o tagata mamaʻi ma le masani ai o tumors. Immunotherapy ma monoclonal antibodies, pei o le nivolumab ma ipilimumab, e ono fesoasoani i le tino o le tino i osofaʻiga o le kanesa, ma ono faʻalavelave ai ile mafai o sela tuma e tutupu ma sosolo. O lenei faʻamasinoga e lesitalaina ai sui mo vaega o loʻo mulimuli mai faʻavae i luga o tuutuuga: 1. Epithelial tumors of nasal cavity, sinuses, nasopharynx: A) Squamous cell carcinoma with variants of nasal cavity, sinuses, ma nasopharynx ma trachea (le aofia ai laryngeal, nasopharyngeal kanesa [NPC] , ma squamous sela kanesa o le ulu ma le ua [SCCHN]) B) Adenocarcinoma ma fesuiaiga o le ana nasal, sinus, ma nasopharynx (tapunia i accrual 07/27/2018) 2. Epithelial tumors o tele salivary glands (tapunia i accrual 03 / 20/2018) 3. Salivary gland type tumors o le ulu ma le ua, laugutu, esophagus, manava, manava ma mama, susu ma isi nofoaga (tapunia i accrual) 4. Le afaina le kanesa o gastrointestinal (GI) tract 5. Adenocarcinoma ma ituaiga o laʻau laiti (tapunia i accrual 05/10/2018) 6. O le sela o le sela sela ma ituaiga eseese o le GI (manava laʻau manava, kolone, tumutumu, pancreas) (tapunia i le accrual 10/17/2018) 7. Fibromixoma ma le maualalo vasega mucous adenocarcinoma (pseudomixoma peritonei) o le faʻaopoopoga ma ovary (tapunia i accrual 03/20/2018) 8. Laʻitiiti pancreatic tumors aofia ai acinar sela carcinoma, mucinous cystadenocarcinoma po serous cystadenocarcinoma. O le Pancreatic adenocarcinoma e le agavaʻa 9. Intrahepatic cholangiocarcinoma (tapuni i le faʻamaumauga 03/20/2018) 10. Extrahepatic cholangiocarcinoma ma bile duct tumors (tapunia i le faʻamautuina 03/20/2018) 11. Sarcomatoid carcinoma o le tino 12. Bronchoalveolar carcinoma māmā. Lenei tulaga ua taua foi o le adenocarcinoma i le mea e tupu ai, adenocarcinoma osofaʻi laititi, adenocarcinoma sili ona malosi lepidic, poʻo le faʻamalosi mucinous adenocarcinoma 13. E le o epithelial tumors o le ovary: A) Siama sela tuma o ovary B) Mullerian fefiloi ulu ma adenosarcoma (tapunia 14. Faʻatupuga ole Trophoblastic: A) Choriocarcinoma (tapunia ile faʻaputuputuina) 15. O le sela ole sela e leʻo iai le fatugaʻo, pelvis, ureter, poʻo le tagāmimi (tapuni ile faʻaputuga) testis ma tumo siama extragonadal: A) Seminoma ma testicular feusuaʻiga kanesa B) Non-seminomatous tuma C) Teratoma ma malignant suiga (tapunia i accrual) 17.
Nofoaga: 895 nofoaga
Suʻesuʻe mataalia, Bleomycin, Carboplatin, Etoposide, poʻo le Cisplatin i le togafitia o Tamaiti ma Tagata Matutua Tagata Maʻi ma Tumua Siama Lenei vaega III suʻesuʻe suʻesuʻega pe o le a le mataalia o le mataituina, bleomycin, carboplatin, etoposide, poʻo le cisplatin galue i le togafitia o tamaiti ma tagata matutua ma siama sela tuma . O le mataʻu mataalia e ono fesoasoani ai i fomaʻi e mataitu mataʻupu e maualalo le lamatiaga o siama sela pe a uma ona aveʻesea o latou tuma. O fualaʻau e faʻaaogaina i le chemotherapy, pei o le bleomycin, carboplatin, etoposide, ma le cisplatin, e eseese auala e taofi ai le tuputupu aʻe o sela tuma, a le o le fasiotia o sela, e ala i le taofiina mai le vaeluaina, poʻo le taofia o latou mai le sosolo. Nofoaga: 460 nofoaga
Inotuzumab Ozogamicin ma Post-Induction Chemotherapy i le togafitia o tagata mamaʻi ma maualuga le lamatiaga B-ALL, Mixed Phenotype Acute Leukemia, ma B-LLy
Lenei vaega III suʻesuʻega suʻesuʻega pe o inotuzumab ozogamicin na faʻaopopoina i le post-induction chemotherapy mo tagata mamaʻi ma High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) faaleleia atili taunuʻuga. O lenei faʻataʻitaʻiga e suʻesuʻeina foi iuga o tagata mamaʻi ma le fenumiai ogaoga leukemia (MPAL), ma le B-lymphoblastic lymphoma (B-LLy) pe a togafitia ma UMA togafitiga e aunoa ma inotuzumab ozogamicin. Inotuzumab ozogamicin o le monoclonal antibody, e taʻua o le inotuzumab, e fesoʻotaʻi ma se ituaiga o chemotherapy e taʻu o le calicheamicin. Inotuzumab faʻapipiʻi i sela kanesa i se auala faʻatulagaina ma tilivaina calicheamicin e fasioti i latou. O isi vailaʻau o loʻo faʻaaogaina i le chemotherapy regimen, e pei o cyclophosphamide, cytarabine, dexamethasone, doxorubicin, daunorubicin, methotrexate, leucovorin, merc laptopurine, prednisone, thioguanine, vincristine, ma pegaspargase galue i auala eseese e taofi ai le tuputupu ae o sela kanesa, a le o le fasiotia o sela, ala i le taofiina latou mai le vaeluaina, pe i le taofiina latou mai le sosolo. O lenei faʻamasinoga o le a suʻesuʻeina foi iʻuga o tagata mamaʻi ma le fenumiai ogaoga leukemia (MPAL) ma faʻasalalauina B lymphoblastic lymphoma (B-LLy) pe a togafitia ma maualuga le tulaga lamatia chemotherapy. O le aotelega o sini o lenei suʻesuʻega o le malamalama pe afai o le faʻaopopoina o le inotuzumab ozogamicin i le tulaga masani o le togafitiga o le chemotherapy o loʻo tumau pe faʻaleleia atili ai iʻuga o le High Risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL). O le vaega muamua o le suʻesuʻega e aofia ai vaega muamua e lua o togafitiga: Induction ma Consolidation. Lenei vaega o le a aoina faʻamatalaga i luga o le lukimia, faʻapea foi ma aʻafiaga o le amataga togafitiga, ina ia mafai ona faʻavasega tagata mamaʻi i le maeʻa-tuʻufaʻatasia vaega togafitiga. I le vaega lona lua o lenei suʻesuʻega, o tagata gasegase o le a mauaina le toega o le chemotherapy uila (tumau le tumau I, tuai faʻamalosia, le tumau tausiga II, tausiga), ma nisi tagata gasegase faʻasolosolo e mauaina inotuzumab. O isi faʻamoemoe o lenei suʻesuʻega e aofia ai le suʻesuʻeina poʻo le togafitia o aliʻi ma tamaʻitaʻi e tutusa le umi o le chemotherapy o loʻo tumau pea taunuʻuga mo aliʻi na muamua faʻataʻitaʻia mo le tausaga faʻaopopo pe a faʻatusatusa i teineiti, faʻapea foʻi ma le iloiloina o auala sili e fesoasoani ai i tagata mamaʻi ia faʻalogo i gutu. regimens chemotherapy. I le iuga, o lenei suʻesuʻega o le a muamua suʻesuʻeina taunuʻuga o mataupu ma faʻasalalau B-cell Lymphoblastic Leukemia (B LLy) poʻo Mixed Phenotype Acute Leukemia (MPAL) pe a togafitia ma B-ALL chemotherapy. tagata mamaʻi o le a mauaina le toega o le chemotherapy uila (tumau le tumau I, tuai faʻamalosia, le tumau tausiga II, tausiga), ma nisi tagata gasegase faʻasolosolo e mauaina inotuzumab. O isi faʻamoemoe o lenei suʻesuʻega e aofia ai le suʻesuʻeina poʻo le togafitia o aliʻi ma tamaʻitaʻi e tutusa le umi o le chemotherapy o loʻo tumau pea taunuʻuga mo aliʻi na muamua faʻataʻitaʻia mo le tausaga faʻaopopo pe a faʻatusatusa i teineiti, faʻapea foʻi ma le iloiloina o auala sili e fesoasoani ai i tagata mamaʻi ia faʻalogo i gutu. regimens chemotherapy. I le iuga, o lenei suʻesuʻega o le a muamua suʻesuʻeina taunuʻuga o mataupu ma faʻasalalau B-cell Lymphoblastic Leukemia (B LLy) poʻo Mixed Phenotype Acute Leukemia (MPAL) pe a togafitia ma B-ALL chemotherapy. tagata mamaʻi o le a mauaina le toega o le chemotherapy uila (tumau le tumau I, tuai faʻamalosia, le tumau tausiga II, tausiga), ma nisi tagata gasegase faʻasolosolo e mauaina inotuzumab. O isi faʻamoemoe o lenei suʻesuʻega e aofia ai le suʻesuʻeina poʻo le togafitia o aliʻi ma tamaʻitaʻi e tutusa le umi o le chemotherapy o loʻo tumau pea taunuʻuga mo aliʻi na muamua faʻataʻitaʻia mo le tausaga faʻaopopo pe a faʻatusatusa i teineiti, faʻapea foʻi ma le iloiloina o auala sili e fesoasoani ai i tagata mamaʻi ia faʻalogo i gutu. regimens chemotherapy. I le iuga, o lenei suʻesuʻega o le a muamua suʻesuʻeina taunuʻuga o mataupu ma faʻasalalau B-cell Lymphoblastic Leukemia (B LLy) poʻo Mixed Phenotype Acute Leukemia (MPAL) pe a togafitia ma B-ALL chemotherapy. O isi faʻamoemoe o lenei suʻesuʻega e aofia ai le suʻesuʻeina poʻo le togafitia o aliʻi ma tamaʻitaʻi e tutusa le umi o le chemotherapy o loʻo tumau pea taunuʻuga mo aliʻi na muamua faʻataʻitaʻia mo le tausaga faʻaopopo pe a faʻatusatusa i teineiti, faʻapea foʻi ma le iloiloina o auala sili e fesoasoani ai i tagata mamaʻi ia faʻalogo i gutu. regimens chemotherapy. I le iuga, o lenei suʻesuʻega o le a muamua suʻesuʻeina taunuʻuga o mataupu ma faʻasalalau B-cell Lymphoblastic Leukemia (B LLy) poʻo Mixed Phenotype Acute Leukemia (MPAL) pe a togafitia ma B-ALL chemotherapy. O isi faʻamoemoe o lenei suʻesuʻega e aofia ai le suʻesuʻeina poʻo le togafitia o aliʻi ma tamaʻitaʻi e tutusa le umi o le chemotherapy o loʻo tumau pea taunuʻuga mo aliʻi na muamua faʻataʻitaʻia mo le tausaga faʻaopopo pe a faʻatusatusa i teineiti, faʻapea foʻi ma le iloiloina o auala sili e fesoasoani ai i tagata mamaʻi ia faʻalogo i gutu. regimens chemotherapy. I le iuga, o lenei suʻesuʻega o le a muamua suʻesuʻeina taunuʻuga o mataupu ma faʻasalalau B-cell Lymphoblastic Leukemia (B LLy) poʻo Mixed Phenotype Acute Leukemia (MPAL) pe a togafitia ma B-ALL chemotherapy.
Nofoaga: 189 nofoaga
Faatelevaveina poʻo le masani ai BEP Chemotherapy i le togafitia o tagata mamaʻi i le feololo poʻo le leaga o le lamatiaga Metastatic germ sela tuma
O lenei randomized phase III faʻataʻitaʻiga suʻesuʻega pe faʻafefea ona saoasaoa le faʻatulagaina o le bleomycin sulfate, etoposide phosphate, ma le cisplatin (BEP) chemotherapy galue pe a faʻatusatusa i le faʻatulagaga masani o le BEP chemotherapy i le togafitia o tagata mamaʻi i le feololo poʻo le le mautinoa o siama siama tuma na sosolo i isi nofoaga i le tino (metastatic). O fualaʻau o loʻo faʻaaogaina i le chemotherapy, pei o le bleomycin sulfate, etoposide phosphate, ma le cisplatin, e eseese auala e taofi ai le tuputupu aʻe o sela tuma, a le o le fasiotia o sela, e ala i le taofiina mai le vaeluaina, pe taofi le sosolo. O le mauaina o le BEP chemotherapy i luga o le televave, poʻo le "televave" faʻatulagaina e mafai ona sili atu le lelei ma le laʻititi ni aʻafiaga i le togafitia o tagata mamaʻi i le ogatotonu poʻo le le lelei le lamatiaga metastatic germ cell tumors faʻatusatusa i le masani taimi.
Nofoaga: 139 nofoaga
Faʻaola le faʻamatalaga auto-toefaʻafou